Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Flushing, Hyperlipidemias, Dyslipidemias
Interventions: Psyllium, Aspirin; Dietary Supplement · Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure, Burn Pit Exposure, Forever Chemicals, Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemia (E.G., Hypercholesterolemia)
Interventions: Colesevelam, Placebo; Drug
Lead sponsor: University of Rhode Island; Other
Eligibility: 25 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Louisville, Kentucky • Augusta, Maine

Conditions: Hypercholesterolemia
Interventions: Bococizumab (PF-04950615; RN316); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 6
States / cities: Anaheim, California • South Miami, Florida • Overland Park, Kansas + 1 more

Conditions: Hyperlipidemia
Interventions: Policosanol supplement (oral capsule) vs. placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 168
States / cities: Birmingham, Alabama • Huntsville, Alabama • Ozark, Alabama + 135 more

Conditions: Cardiovascular Diseases, Hypertension, Hyperlipidemias, Dyslipidemias, Obesity, Diabetes Mellitus, Tobacco Use Disorder, Overweight
Interventions: CV Toolkit Components; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 6,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Sepulveda, California • West Los Angeles, California • West Haven, Connecticut + 1 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin calcium 10 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,311 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 37
States / cities: Hoover, Alabama • McCalla, Alabama • Pinson, Alabama + 32 more

Conditions: Hypertriglyceridemia
Interventions: evinacumab, Placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 32
States / cities: Newport Beach, California • New Haven, Connecticut • Boca Raton, Florida + 26 more

Conditions: Hypercholesterolemia, Familial
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: Secura then Futura, Futura then Secura; Device
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Hartford, Connecticut • Kansas City, Kansas

Conditions: Hypertriglyceridemia
Interventions: DHA-rich fish oil versus Phospholipid-rich fish oil; Dietary Supplement
Lead sponsor: Arctic Nutrition AS; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Metabolic Syndrome
Interventions: Grape Seed Extract, Placebo; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 20 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Mather, California

Conditions: Cholesterol, Elevated, Clinical Decision Support, Education
Interventions: Interruptive Reminder, Non-interruptive Reminder, No Reminder; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
Interventions: Medication Metronome, Usual Care; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Coronary Disease
Interventions: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 79 Years
Enrollment: 7,287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Minneapolis, Minnesota • Winston-Salem, North Carolina • Cleveland, Ohio + 1 more

Conditions: Hypertension, Hypercholesterolemia, Diabetes, Medication Adherence
Interventions: Refill synch; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 691 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Hyperglycemia, Hyperlipidemia
Interventions: Olanzapine, Ziprasidone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions: Evolocumab Pre-filled Syringe, Evolocumab AI/pen; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 21
States / cities: Encino, California • Thousand Oaks, California • Ventura, California + 17 more

Conditions: Hypercholesterolemia, Cardiovascular Diseases
Interventions: lerodalcibep, evolocumab, alirocumab; Biological
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: Dyslipidaemias
Interventions: GW590735, fenofibrate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more

Conditions: Hyperlipidemia
Interventions: K-312 10 mg QD, K-312 25 mg QD, K-312 50 mg QD, K-312 100 mg QD, K-312 200 mg QD, K-312 400 mg QD, Placebo; Drug · Other
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Interventions: obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo; Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 32
States / cities: Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more

Conditions: Atherosclerosis, Hyperlipidemia
Interventions: Alirocumab; Drug
Lead sponsor: Westside Medical Associates of Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Heart Diseases
Interventions: Exercise training; Other
Lead sponsor: East Tennessee State University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 1998
U.S. locations: 1
States / cities: Johnson City, Tennessee

Search by objective public record fields.

Effects of Psyllium on Niacin Tolerability

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

Policosanol for the Treatment of Hypercholesterolemia

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

Cardiovascular Risk Screening and Risk Reduction in Women Vets

Actual Use Trial of Atorvastatin Calcium 10 mg

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia

(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

Bioavailability of EPA and DHA From Two Dietary Supplements

Effect of a Grape Seed Extract (GSE) on Insulin Resistance

Statin Reminders for Improving Prescribing in Primary Care

The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care

Intensive Glycemic Control and Skeletal Health Study

The Effect of Synching Prescription Refills on Adherence

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab

Exercise as a Modulator of Immune Risk Factors for Ischemic Heart Disease